Search
MORF-057
go.drugbank.com/drugs/DB23674InvestigationalMORF-057 is under investigation in clinical trial NCT06226883 (A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease).
Brepocitinib
go.drugbank.com/drugs/DB15003ApprovedInvestigationalBrepocitinib is an oral Janus kinase (JAK) and tyrosine kinase 2 (TYK2) inhibitor used to treat dermatomyositis in adults.
Starch, corn
go.drugbank.com/drugs/DB11599ApprovedInvestigationalNutraceuticalCorn starch refers to the starch extracted from the corn grain that is commonly used as a food ingredient and chemical additive.
Mianserin
go.drugbank.com/drugs/DB06148ApprovedWithdrawnA tetracyclic compound with antidepressant effects. Mianserin was previously available internationally, however in most markets it has been phased out in favour of mirtazapine.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeGlucose-6-Phosphate
go.drugbank.com/drugs/DB03581ExperimentalAn ester of glucose with phosphoric acid, made in the course of glucose metabolism by mammalian and other cells.
D-Asparagine
go.drugbank.com/drugs/DB03943ExperimentalIt is biosynthesized from ASPARTIC ACID and AMMONIA by asparagine synthetase. (From Concise Encyclopedia Biochemistry and Molecular Biology, 3rd ed)
IDM-1
go.drugbank.com/drugs/DB05292ExperimentalIt is comprised of MAK(Monocytes-derived Activated Killer) cells associated with MDX-210, a bispecific anti-HER-2/neu antibody developed by Medarex Inc.
Autologous Non-Hematopoietic Peripheral Blood Stem Cells
go.drugbank.com/drugs/DB15867InvestigationalAutologous non-hematopoietic peripheral blood stem cells have been created into a formulation for use in a clinical trial (NCT04473170) by the Abu Dhabi Stem Cells Center.
Jaktinib
go.drugbank.com/drugs/DB17545InvestigationalJaktinib is a JAK 1, JAK 2 and JAK 3 inhibitor, being developed by Suzhou Zelgen Biopharmaceuticals.
Edodekin alfa
go.drugbank.com/drugs/DB15631Investigationalinvestigation in clinical trial NCT01468896 (Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That Is Recurrent, Metastatic, or Cannot Be Removed by